News Conference News ACC 2023 IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF L.A. McKeown March 14, 2023
News Daily News Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths Michael O'Riordan December 08, 2022
News Conference News AHA 2022 EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD Todd Neale November 06, 2022
News Conference News AHA 2022 TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF Todd Neale November 05, 2022
News Conference News AHA 2022 Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions Yael L. Maxwell November 01, 2022
News Daily News AHA Urges More Home-Based Dialysis in Advanced Kidney Failure Michael O'Riordan August 18, 2022
News Conference News ESC Heart Failure 2022 HF Triple Therapy Doesn’t Seem Effective in True Preserved HF Shelley Wood May 25, 2022
News Daily News Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries Todd Neale April 20, 2022
News Daily News Guideline-Directed Therapies Underused in Frail HF Patients L.A. McKeown March 11, 2022
News Conference News AHA 2021 Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF Michael O'Riordan November 19, 2021
News Conference News AHA 2021 Empagliflozin Retains Benefits in ‘True’ HFpEF Patients Todd Neale November 17, 2021
News Conference News AHA 2021 Canagliflozin Improves Quality of Life in HF Patients Michael O'Riordan November 16, 2021
News Daily News Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results Todd Neale July 06, 2021
News Conference News ACC 2021 Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF Michael O'Riordan May 25, 2021
News Daily News AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More Shelley Wood December 17, 2020